MLL Dx Successfully Accredited by the College of American Pathologists (CAP)
MLL Dx, the sister company of the Munich Leukemia Laboratory (MLL) with its MLLSEQ brand, was appraised by the College of American Pathologists (CAP) and successfully accredited according to their requirements. Since 2019, MLL Dx has been accredited according to the international standards DIN EN ISO 15189 “Medical Laboratories – Requirements for Quality and Competence” and DIN EN ISO/IEC 17025 “General Requirements for the Competence of Testing and Calibration Laboratories” by the Deutsche Akkreditierungsstelle (German Accreditation Body – DAkkS).
The CAP is a medical organization founded in 1946, to which around 18,000 certified pathologists belong. The task of the CAP is to promote and represent the best practices in pathology and laboratory medicine. The CAP offers medical laboratories accreditations and suitability tests and also publishes checklists with requirements for conducting laboratory tests. Their standards are accepted as the strictest and most demanding in the medical industry. The CAP accreditation system for laboratories is based on globally, objectively verifiable quality standards, thereby generating both comparability and mutual trust.
“The fact that MLL Dx has been successfully accredited by the CAP is very important to us. Quality and constant improvement are a high priority for us and play an enormous role in our everyday work. As with our DakkS accreditations, the CAP accreditation confirms that we adhere to very high quality standards,” said Prof. Dr. med. Wolfgang Kern, founder and managing director of the MLL.
MLL Dx was founded in 2017 as a sister company of the MLL and offers comprehensive leukemia and lymphoma diagnostics for foreign patients and as part of clinical studies. The services and knowledge of the MLL and MLL Dx are directly interconnected, guaranteeing patients the best possible diagnostics according to the current state of the art. Both companies have embodied high quality and constant improvement since they were founded.